Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data Transcript
Good day, ladies and gentlemen, and welcome to the Madrigal Pharmaceuticals MAESTRO-NAFLD-1 Top Line data Conference Call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Dr. Paul Friedman, Chairman and Chief Executive Officer of Madrigal. Dr. Friedman, you may begin.
Thank you. Good morning, and thanks for joining our call. Next slide. This is a fine print dealing with our forward-looking statements, please see today's press release and our SEC filings for forward-looking statements and risk factor considerations associated with these statements and our business.
Next slide. The purpose of this call is to review top line data from our Phase III MAESTRO-NAFLD-1 study of resmetirom. And as most of you have probably seen, we issued a press release this morning with the results we'll be referencing on the call. Before turning the call over to Becky Taub to summarize the data, I'd like to share some initial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)